Exelixis, Inc.

NASDAQ:EXEL

Biotechnology

Healthcare
$68.29 +0.65%

+$0.34 today

Market cap
$17.17B
Beta
0.43
P/E (TTM)
16.3
EPS (TTM)
$3.23
52W Low $33.76High $53.93

Volume 1.82M

Average 2.55M

EXEL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Exelixis, Inc.NASDAQ: EXEL

Research & Development · Q2 FY2026 · quarter ended Jul 2026

Research & development growth accelerates

Q2 FY2026 research & development of $211.99M rose 5.8% year over year, ahead of the -6.8% change in trailing-twelve-month research & development. Sequentially, it rose 6.0% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.

Context

  • Research & development amounted to 35.6% of revenue in FY2025, down 6.4 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +5.8% holds above the trailing-twelve-month pace of -6.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJul 2026
$211.99M+6.0% QoQ
Last fiscal yearJan 2026
$825M-9.4% YoY
LTMJul 2026
$824.32M-6.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.8%——
1 year-9.4%——
3-year CAGR-2.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
825M USD
Year-over-year change
-9.4%
4-year CAGR
+4.4%

Research & Development vs competitors

How EXEL compares with its peers on the latest reported figures

  • EXEL's LTM Jul 2026 research & development of $824.32M is the 5th highest of the 8 companies compared; the peer median is $1.29B.
  • Its year-over-year change of -6.8% is the 6th highest of 7, against a peer median of +6.4%.
  • Research & development amounts to 33.8% of revenue for EXEL, versus a peer median of 34.3%.
EXEL Competitors Peer median
Research & Development for EXEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AZNAstraZeneca PLCLTM Sep 2026$15.01B -0.3%+13.4%24.1%
INCYIncyte CorporationLTM Jun 2026$2.15B +9.1%+8.9%37.0%
GMABGenmab A/SLTM Jun 2026$1.78B —-34.5%43.1%
RVMDRevolution Medicines, Inc.LTM Jun 2026$1.29B +68.1%+57.0%—
EXELExelixis, Inc.LTM Jul 2026$824.32M -6.8%-2.6%33.8%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$255.99M +3.7%+29.7%117.9%
HCMHUTCHMED (China) LimitedLTM Jun 2025$190.1M -25.1%-15.0%31.6%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$36.54M +41.7%-17.9%12.2%
Peer median (excluding EXEL) $1.29B+6.4%+8.9%34.3%

Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.43B1.61B1.83B2.17B2.32B
Cost of Revenue52.87M57.91M72.55M76.22M83.7M
Gross Profit1.38B1.55B1.76B2.09B2.24B
Gross Margin96.3%96.4%96.0%96.5%96.4%
Research & Development693.72M891.81M1.04B910.41M825M
Selling, General & Admin401.72M459.86M542.71M492.13M518.73M
Operating Expenses1.1B1.35B1.59B1.49B1.36B
Depreciation & Amortization13.63M20.88M25.72M28.8M29.06M
EBITDA307.78M255.23M283.24M718.75M921.76M
EBITDA Margin21.4%15.8%15.5%33.1%39.7%
Operating Income286.67M201.48M170.89M604.62M872.19M
Operating Margin20.0%12.5%9.3%27.9%37.6%
Interest Income7.67M33.07M86.54M77.16M69.21M
Interest Expense00000
Other Income / Expenses7.49M32.87M86.64M77.02M69.02M
Income Before Tax294.15M234.35M257.52M681.64M941.21M
Pre-Tax Margin20.5%14.5%14.1%31.4%40.6%
Income Tax Expense63.09M52.07M49.76M160.37M158.64M
Net Income231.06M182.28M207.77M521.27M782.57M
Net Margin16.1%11.3%11.4%24.0%33.7%
EPS (Basic)0.730.570.651.802.88
EPS (Diluted)0.720.560.651.762.78
Weighted Avg Shares314.88M321.53M318.15M290.03M271.57M
Weighted Avg Shares (Diluted)322.36M324.56M321.46M296.13M281.86M

Exelixis, Inc.

NASDAQ:EXEL

Intrinsic Alpha fair value

Locked

Current Price

$68.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.